This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n12http://dx.doi.org/10.1023/A:
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q43719053
rdf:type
wikibase:Item
schema:description
vetenskaplig artikel artigo científico 2001 nî lūn-bûn জুলাই ২০০১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article published in July 2001 2001年学术文章 научни чланак wetenschappelijk artikel מאמר מדעי bài báo khoa học scientific article published in July 2001 videnskabelig artikel 2001年學術文章 مقالة علمية نشرت في يوليو 2001 наукова стаття, опублікована в липні 2001 artikulong pang-agham 2001年學術文章 naučni članak 2001年学术文章 artículu científicu espublizáu en 2001 научна статия article científic 2001年学术文章 bilimsel makale articol științific scienca artikolo 2001年學術文章 სამეცნიერო სტატია 2001年学术文章 2001年學術文章 article scientific επιστημονικό άρθρο article scientifique vitenskapelig artikkel wissenschaftlicher Artikel artigo científico мақолаи илмӣ tieteellinen artikkeli 2001年の論文 tudományos cikk บทความทางวิทยาศาสตร์ artikel ilmiah 2001年学术文章 научни чланак artigo científico scientific article published in July 2001 научная статья vedecký článok 2001年学术文章 vitskapeleg artikkel artículo científico publicado en 2001 2001年學術文章 teaduslik artikkel vědecký článek artikull shkencor 2001년 논문 artykuł naukowy articolo scientifico مقالة علمية تنشرت ف 1 يوليوز 2001
p:P577
wds:Q43719053-BBC9600E-4093-4F9B-9316-96136F57F2F3
wdt:P577
2001-07-01T00:00:00Z
p:P2860
wds:Q43719053-4DDE3BE7-0325-46AA-9603-ED58A9E53737 wds:Q43719053-6953346A-8721-4C7B-83F6-F8AAD3E63A4E wds:Q43719053-76AB7ED2-ECC3-4D50-B32C-0BB6B12B36F6 wds:Q43719053-9CDA7716-2568-4623-AF73-967902442E0D wds:Q43719053-C2FE2EC9-A8F1-422B-8DCA-261459804E5D wds:Q43719053-C9A3890F-1AF6-4FA4-BF96-353BEE82D165 wds:Q43719053-170F410E-4B74-4789-8795-166B8FD1F433 wds:Q43719053-1C78218E-F9D8-4B43-8B61-826E5C93372C wds:Q43719053-233A2690-1683-4972-B938-DDAAF2A837A8 wds:Q43719053-2D1FE066-96AB-427F-AC63-BA9D17268C37 wds:Q43719053-36F25EF7-5720-48EB-BE7B-E8A1B696D5FD wds:Q43719053-FC26FF4B-8088-472F-B12E-A34FC34C5A72
wdt:P2860
wd:Q36620007 wd:Q24563363 wd:Q73418817 wd:Q73919503 wd:Q33880642 wd:Q43503967 wd:Q34086156 wd:Q73047951 wd:Q73486068 wd:Q78167219 wd:Q34047386 wd:Q34292940
p:P2093
wds:Q43719053-186B9016-3041-418B-ADC6-16DD9AEC8CB2 wds:Q43719053-176F7CFF-CD14-408A-A9A9-609747CA7560 wds:Q43719053-1830A350-CED5-44D1-9636-27523250B5A7 wds:Q43719053-1537B6AC-3A4F-44EE-B139-4592876F2554 wds:Q43719053-3DA73FDB-B2AB-48CB-8690-DEDF552BFE3F wds:Q43719053-3186E90F-C326-40CE-8D55-547BD51C10F6 wds:Q43719053-24B27AB9-DF54-4566-93EA-AB9444BE5E4F wds:Q43719053-69DF978C-BCD7-4DEE-A685-E0E24C2EA67A wds:Q43719053-EA4D058F-55B5-4F24-8B1D-5DA3843FAE7D wds:Q43719053-A331376E-A66A-4998-A86B-C19CCC366654 wds:Q43719053-12B9B6D1-F3AC-4130-9B2C-34D987AC26AB
wdt:P2093
A Burlini S Cinieri E Cocorocchio W Mingrone P Mancuso G Martinelli F Peccatori F Bertolini A Alietti C Corsini E Zucca
rdfs:label
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
skos:prefLabel
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
schema:name
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
p:P50
wds:Q43719053-3AB9CB35-9C2C-4D0C-9B55-04157610945E
wdt:P50
wd:Q42682251
p:P1476
wds:Q43719053-5AF8A212-210F-4E8E-B1D4-CAC87A3CFF73
wdt:P1476
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
p:P304
wds:Q43719053-9DCD5D43-60CC-402F-A5B9-813751EAEEC2
wdt:P304
987-990
p:P31
wds:Q43719053-E37390AE-5AD3-4AC7-AC72-9C56B02DC536
wdt:P31
wd:Q13442814
p:P921
wds:Q43719053-6CF2783F-3F29-4AC6-B3EF-792E20165883 wds:Q43719053-0EC17951-0060-4972-AE60-E0E690E8775E
wdt:P921
wd:Q467635 wd:Q203174
p:P698
wds:Q43719053-EF6ACFD4-D327-4A55-94EF-3C114C325E56
wdtn:P698
n7:11521807
wdt:P698
11521807
p:P1433
wds:Q43719053-4CEE4E21-8151-44B8-9781-40D75262F9EF
wdt:P1433
wd:Q326122
p:P433
wds:Q43719053-B96EC18B-4FAE-404D-BC77-C8031D4A4520
p:P478
wds:Q43719053-236431C1-AA73-47B7-BF6E-665FEEB29A58
wdt:P433
7
wdt:P478
12
p:P356
wds:Q43719053-148F0635-71F9-4DFA-9C4A-FC98AE867E40
wdtn:P356
n12:1011141009812
wdt:P356
10.1023/A:1011141009812
p:P5875
wds:Q43719053-1A3D6638-54E8-4980-9B01-D0EEA1A9D02D
wdt:P5875
11823629